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1. Introduction 
The problem of cancer embraces a lot of unresolved issues, among which there dominates 
the problem of ascertainment of the mechanisms of uncontrolled growth and cellular spill of 
tumor neoplasm, composed of dividing cancer cells and cancer stem cells (Schatton & Frank 
MH, 2009; Schatton et al., 2009; Frank NY et al., 2010). It is impossible to answer the 
question about a complete removal of the tumor tissue and simultaneous minimizing 
the adverse effects of surgical and other manipulations while removing the tumor without 
solving this problem. This is a particularly relevant goal for physicians who are engaged in 
treatment of brain tumors. The destruction of nerve tissue nonaffected by tumor growth has 
a negative impact on the integrative brain activity and at least on the central control of all 
bodily functions and homeostasis maintenance. How is it possible to reduce by-effects of 
major therapeutic technologies in neurooncology (surgical, radiological, chemotherapeutic), 
having preserved or enhanced their selective tumor damaging action? 
Since you choose chemotherapy as one of the ways to impact on tumor tissue, it is 
impossible not to mention the commonly known toxic effect of chemotherapeutic agents on 
all body tissues. Destroying the tumor cells, cytotoxic agents kill healthy cells and tissues. 
Thus, local or systemic applying the chemotherapy leads inevitably to the destruction 
of healthy brain cells in case of the tumor localization within the cranial cavity and the 
spinal canal. Thus, one of the objectives of this work was to develop methodic of leveling 
the general toxic effects of chemotherapy while strengthening their local destructive 
effect on tumor tissue. What ways have been chosen to solve this problem? 
Tumors of the brain and spinal cord have extremely variety (set) of histological forms which 
are accounted for their origin from the elements of various tissues and for peculiarity of 
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genesis not solved up to the end in respect to especially neuroepithelial tumors (Hirose & 
Yoshida, 2006; Nicholas et al., 2011; Van den Eynde et al., 2011). The nervous system tumors 
account for almost 10% of all human neoplasms, and up to 20% for children (Alomar, 2010; 
Davis et al., 2010; Myung et al., 2010). Neoplasms of brain and spinal cord are the most 
common solid tumors in childhood. They take the second place in frequency after leukemia 
of all child malignancies. In childhood (under 14 years) the vast majority of cases occur in 
neuroepithelial tumors. Of these, about 80% are of six histological forms: medulloblastoma, 
juvenile pilocytic astrocytoma, diffuse astrocytoma, ependymoma, craniopharyngioma, and 
neuroblastoma. 
Among the tumors of neuroepithelial tissues 9 sub-groups are selected out: astrocytic, 
oligodendroglial, ependymal, oligoastrocytic tumors (mixed gliomas), tumors 
of vascular plexus, and other neuroepithelial tumors (glial tumors of unspecified origin), 
neuronal and neuronal-glial, pineal, and embryonal tumors. In most cases glial tumors 
(gliomas) such as astrocytic, oligodendroglial, and ependymal glioma ones are detected. 
Histological diagnosis was based on identifying the predominant cell type.  
Combined treatment of the brain cancer (children including), which supposes surgery 
interference together with chemo- and radiotherapy, does not so far reach the desired 
impact. According to statistics concerning only medulloblastoma, the average disease-
free and overall survival during 2-7 years for patients up to 4 years old is respectively 
46% and 54%. So, tiny comforting is aggravated by data that uniquely ascertain the growth 
of intracerebral cancer. Thus, in the U.S. during 30 years from 1973 to 2003 it increased from 
4.1 to 5.2 for women and from 5.9 to 7.0 for men per 100 000 population (Alomar, 2010). 
Similar dynamics were recorded by The Child Cancer Registry of the Belarusian Republic. 
The percentage of brain tumors rose from 2.5 to 3.3 per 100 000 children living in Belarus 
from 1989 to 2005. 
A number of intractable causes is due to a low curability of brain tumors. The 
most productive radical method of removal of cancer neoplasm is often limited by the fact 
of their location near vital centers. Courses of medical and radiation treatment in 
accordance with approved protocols HIT`91, PO/02-PO/04 (Dunkel et al., 2010; Rosenfeld 
et al., 2010) along with known positive ones embrace recognizable negative aspects. To the 
negative ones there pertain as follows: i) a low permeability of the blood-brain barrier being 
created by tight contacts of micro vessel intracerebral network, which became completed 
with a set of proteins (Claudine 1,5, Occludin and others), which are impermeable to 
hydrophilic low soluble compounds exceeding a diameter of 18 Å and a molecular weight of 
180 Da. The vast majority of cytotoxic drugs pertain to them (Erdlenbruch et al., 2000; 
Kemper et al., 2004; Xie et al., 2005); ii) a weak selectivity of the concentration of cytostatic in 
the place of neoplasm (Cragnolini & Friedman, 2008); iii) an insufficiently studied 
mechanism of the action of traditional and new pharmacological agents, as well as their 
clearance, which hinders a reasonable estimation of the amount of molecules that come in 
direct contact with tumor cells (Gerstner & Fine, 2007; Ta et al., 2009); iv) a lack of unified 
schemes of medical product application, taking into account the morphological structure of 
complex heterogeneous neoplasias, stages of their malignancy, and individual sensitivity of 
the tumor cells to them and patient age (Alomar, 2010; Myung, et al., 2010); v) a 
symptomatic toxic side effect, reduced to a violation of general tissue metabolism and 
endocrine function, to immunity suppression, involvement in a destructive reaction of 
abnormal elements along with intact (healthy) cell ones, as well as the development of 
complications (acute arachnoiditis, meningo encephalopathy, renal failure, passing 
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deviation from the motor areas, speech, vision, hearing, stop of growth, and cognitive 
deficits with reduced intelligence), what in totality leads to disability (Kemper et al., 2004; 
Vega et al., 2003); vi) a limited range of available medications. 
The postulates set forward underline the actuality of further improving of existing strategies 
and creating new ones for earlier diagnosis, prognosis and a more successful fight against 
cancer. One of the ways to the aim is a broad involvement in oncology of a very 
representative class of multifunctional endogenous biological regulators of peptide nature, 
generally called as growth factors. In own structure they number a series of families, among 
which are neurotrophins (Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor 
(BDNF), Neurotrophins 3, 4, 5 (NT), Transforming Growth Factor (TGF), Fibroblast Growth 
Factor ( FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), 
Insulin-Like Growth factor (IGF), and others, rating more than 50 different variants 
(Antonelli et al., 2007; Beebe et al., 2003). The key role belongs to growth factors in the 
capacity of epigenetic "directive" signals in the control of such fundamental morphogenetic 
processes in ontogenesis as growth, survival, proliferation, differentiation (i.e., the selection 
of the terminal tract of specialization by stem and progenitor cells), guided migration and 
elongation processes, synaptogenesis, regulation of cell homeostasis by apoptosis, 
regeneration, as well as maintaining a normal cyto-biochemical status of mature cells and 
their resistance to damaging factors (Alam et al., 2010; Charles et al., 2011; Vinores & Perez-
Polo, 1983; Xie et al., 2005). 
The interest to determine the significance of these compounds in tumor formation and in 
their reverse transforming potential has just relatively recently emerged, when it became 
vivid that virtually all types of neoplasias are synthesized not only by growth factors but 
actively expressize their receptors (Antonelli et al., 2007; Barnes et al., 2009; Blum & 
Konnerth, 2005; Brossard et al., 2009; Evangelopoulos et al, 2004; Krűttgen et al., 2006; 
Nakagawara, 2001). At the same time we point out a startling fact: NGF was purified for the 
first time from sarcoma secretions S180, and protooncogenes sites, which take it, were 
purified from high-affinity TrkA and low relational P75 from biopsies of colon carcinoma 
(intestinum crassum) and human melanoma. It is much more interesting that bio testing of 
growth factors on its activity is performed on rat pheochromocytoma PC12 (Krűttgen et al., 
2006). 
The experiments proved that in vitro the cell lines of neuroblastoma (IMR-32, SY-5Y, SK-N-
SH, NB-GR) and medullary pheochromocytoma cease to divide in the presence of NGF and 
are transformed into neuron-like elements at braking formation of DNA, at the 
intensification of including labeled amino acids, at the appearance of sprouts, at the growth 
of size, substrate adhesion together with the formation of pseudoganglies and at the 
occurrence in membrane of electrical excitability (Krűttgen et al., 2006; Poluha et al., 
1995). On the other hand, the ability of NGF in vivo to reduce the number of induced 
nitrosourea by neurinomas was revealed, as well as the speed of their development, and the 
ability to reduce the volume and to prolong animal survival after subcutaneous injection or 
intracerebral implantation of anaplastic glioma cell F98, T9, and neurinomas (Yaeger et al., 
1992). The predictive value of identification of perceiving Neurotrophins receptors is 
overviewed. So thus the over expression of TrkA and C (for NT-3) in neuro-, medulla and 
glioblastomas promises a favorable outcome, due to a spontaneous regression (through 
differentiation), the inclusion of suicide programs or autophagy (Blum & Konnerth, 2005; 
Collins, 2004; Krűttgen et al., 2006; Yamaguchi et al., 2007). Patients with low or no 
detectable levels of these receptors in medulloblastoma exhibit 5-fold risk of death than with 
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a high level (Krűttgen et al., 2006). Per contra, the enhanced expression of TrkB (ligand 
BDNF), which takes place in aggressive tumors, where isoforms often truncated and lacked 
of intracellular domain, goes with the pessimistic ending. 
In this light the aim of the research was to study individual and combined effects of some of 
cytostatic and growth factors (Liu et al., 2010), which are in circulation, on the survival of 
primary culture of cells. Alongside an attempt of the combined action of cytostatic, that is 
the factor of Nerve Growth and Dendrimers (or Heterocyclic Compounds) on primary 
culture cells of neuroepithelial tumors was undertaken. Dendrimers are the extended three-
dimensional molecules which contain a large number of active functional groups on the 
outer surface (Morgan et al., 2006; Waite & Roth, 2009). We focused on one of the most 
common types of Dendrimers – Polyamidoamine, (PAMAM), containing ethylenediamine 
core and branching of methyl acrylate and ethylenediamine (Kang et al., 2010). We aimed at 
verifying the hypothesis about the possibility of dose reducing of cytostatic at combined 
application of chemotherapy with growth factors and nanoparticles, in particular 
Dendrimers in these experiments. The fifth generation of Dendrimer (PAMAM G5) was 
used. The effect of combinations of cytostatic, Nerve Growth Factor and Dendrimers or the 
cytostatic agent, Nerve Growth Factor and Heterocyclic Compounds was studied in 
separate series of experiments. Heterocycles of isoxazole series (Isoxazole) and isothiazolyl 
(Isothiazole) (typical representatives of 1,2-azoles) are structural fragments of a wide range 
molecules of active physiologically substances, what causes a growing interest in the 
research of the synthesis and in the study of the biological properties of these compounds. 
Isoxazole heterocycle is a compound part of molecules of the cytotoxic, antitubercular 
agents, anticonvulsants, and pesticides.  
The compounds to be perspective for the treatment of Alzheimer's disease and 
inflammatory, antithrombosis and anticonvulsive drugs were identified among the 
derivatives of isothiazolyl. It was recently found that some isothiazolyls were inhibitors of 
kinases and could be used in the treatment of tumors. For example, isothiazolyl with urea 
function in position 3 is an inhibitor of tyrosine kinases and now it is under studying as an 
anticancer drug CP-547, 632 (Beebe et al., 2003). The fellow-colleagues of Institute of 
Physical Organic Chemistry NAS of Belarus developed methods for the synthesis of new 5-
substituted 1,2-thiazol-3-ilcarbamids and their heteroanalogs – 1,2-oxazole-3-ilcarbamids – 
isosteres known as inhibitors of tyrosine kinases, which are of some interest for testing in 
our planned experiments. The goal of these experiments was to find ways of reducing the 
dose of cytotoxic drugs, under condition of preserving or increasing the toxic effects of 
chemotherapy on tumor tissue. 
2. Methodic 
The biopsy material was taken from 67 children aged from 1 to 15 years old who were 
treated at the children's neurosurgical department of Municipal Clinical Emergency 
Hospital in Minsk from November 2008 to December 2010. 
2.1 The research protocol  
The biopsy material taken during the fine-needle stereotactic or neurosurgical operation was 
transported in an hour to the Pathology Laboratory to determine the histology forms of the 
tumor and degrees of its malignancy, and was simultaneously delivered to the Laboratory 
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of Cell Monitoring to assess individual sensitivity of tumor cells to chemotherapeutic drugs 
in vitro. After the mentioned period 0.5 ml of chemotherapy was added in doses approved 
by instructions and converted either to a square cup (10.0 cm2) or to β-subunit of 
recombinant human NGF (Sigma-Aldrich, USA, 1.0 μg / ml) or to Dendrimers (PAMAM 
0.1, 1.0, 10.0 μg / ml, Sigma-Aldrich, USA), or to heterocyclic compounds (0.1, 1.0, 10.0 μg / 
ml), or to these or others in various combinations. Each series of observations in vitro 
consisted of 30 applications (n = 30). Assessment of the viability of tumor cells was 
estimated in 24 hours after putting test compounds into the environment for their ability to 
incorporate trypan blue. For this matter the cell suspension was mixed with 2% dye solution 
in saline buffer pH = 7.2 at a ratio of 1:10 and transferred into Goryaev’s chamber, where the 
number of dead (paint over) and living (light) elements was counted at a percentage. The 
obtained data were reported to neurosurgeons who together with other specialists 
developed the tactics of post-operative treatment and determined prognosis. 
2.2 Cytoscopic study  
Cytoscopic study of surgical specimens was carried out after using the methods of frozen 
sections, or the crushed drop. The final conclusion of the histological form of the tumor and 
its malignancy degree was made after alcohol treatment, filling material in paraffin, 
sectioning and staining by the following methodic: a method of staining with hematoxylin 
and eosin; histochemical methods for the detection of glial filaments, collagen and reticulin 
fibers; immunohistochemical studies for detection of acidic glial fibrillary protein, 
neurofilaments, synaptophysin, and neuron-specific enolase; a definition of PCNA, Ki-67, 
cyclins in order to clarify the nature of proliferative activity. The conducted cytoscopic 
research allowed to identify indications of malignancy and was a guide to neurosurgeons in 
case of choosing the treatment tactics. 
2.3 Cultural studies  
Pieces of biopsy material were washed from the blood and mechanically comminuted in 
Hank’s solution (Sigma-Aldrich, USA) with Gentamicin sulfate added, and then for 30 min 
they were put in a mixture of 0.25% trypsin solution in Ethylenediaminetetraacetic acid 
(EDTA) (2 ml) at a ratio of 1:3. The effect of the enzyme was inhibited by adding 3 ml Fetal 
Calf Serum – FCS (Sigma-Aldrich, USA) for a period of 3-5 minutes. The material treated in 
such a way was crushed under a microscope with a sterile blade up to pasty consistency and 
then was taken to a sterile Petri dish with medium Dulbecco's Modified Eagle's Medium 
(DMEM) (Sigma-Aldrich, USA), with adding ETS at a ratio of 1:10 and 4% sulfate 
solution Gentamicin (10-4 g / l). The cells obtained from the substrate were grown in a 
medium of this composition for 2-7 days at 37ºC, 95% humidity and 5% partial pressure of 
CO2 (Chekan et al., 2009). Stay duration of the cells in vitro was dictated by the speed of the 
attachment to the substrate. 
2.4 Clinical, laboratory and instrumental methods 
Clinical, laboratory and instrumental methods of the study included a list of routine clinical 
examination methods and laboratory diagnostics, as well as computed tomography and 
nuclear magnetic resonance. The credibility of differences between the average values was 
set by a Mann-Whitney test for nonparametric samples using the computer program 
StatPlus 2005. Differences were estimated to be significant at P <0.05. 
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3. Results 
The following types of cancer were included according to the histological conclusions based 
on classification of brain tumors (WHO, 2007) into the observations: astrocytic, embryonic, 
and compiled under the title "other types" of neoplasm. In the group of cancers of astrocytic 
origin were present: pilocytic, pilomixoidnic, protoplasmic, pleomorphic, anaplastic 
neoplasm. Medulloblastoma, atypical teratoidnic/rabdoidnic tumor of posterior fossa, and 
malignant neuroectodermal tumor of the left temporal lobe were in the category of 
embryonic tumors. The category of "the other options" of neoplasm included: anaplastic 
oligodendrogliomas, oligoastrocytomas of a cerebellar vermis, ependymoma, 
gangliogliomas of a mixed neuroglial type, immature teratoma of a pineal region, which 
was attributable to germinocell tumors, glioma of an optic chiasm, and a gemangioblastoma 
to be regarded as an intramedullary tumor of a cervical spinal cord.  
It was revealed in the experiments in vitro that Cisplatin (Merck, USA, 1.0 μg / ml) took 
priority in the samples of pilocytic astrocytoma, medulloblastoma, and malignant 
neuroectodermal tumors of the temporal lobe, where the percentage of dead cells reached 
respectively 61.9 ± 12.9, 40.9 ± 11.4, 41.6 ± 8.5, 68.6 ± 7.8 reliably exceeding the one in those 
experiments where the cells of a primary culture of neuroepithelial tissue devolved out of 
contact with chemotherapy (14.3 ± 5.0%). A similar position was taken by Carboplatin 
(Merck, USA, 4.0 μg / ml) in biopsies from pleyomorfic xanthoastrocytoma, anaplastic 
oligodendroglioma (Fig. 1), optic chiasm glioma and atypical teratoid / rhabdoid tumors 
(Fig. 2) with lethality according to the order of enumeration 57.9 ± 5.9, 68.4 ± 10.6, 78.9 ± 4.1 
and 79.5 ± 1.0%.  
 
 
Fig. 1. Anaplastic oligodendroglioma 
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Fig. 2. Atypical teratoid / rhabdoid tumor 
The same can be said about Etoposide (Ebewe Artsnaym., Austria, 1.0 μg / ml) in relation to 
the protoplasmic astrocytoma cells (61.0 ± 4.7%), oligoastrocytoma (55.1 ± 8.5%) (Fig. 3 a, b) 
and especially about hemangioblastoma (74.7 ± 3.9%). 
 
    
a     b     c 
Fig. 3. Oligoastrocytoma cell survival in a day after the application of Etoposide (b) and β-
NGF (c) in comparison with intact cells of primary culture of the tumor (a). The 
magnification is x 312.5. 
Cytarabine (Belmedpreparaty, Belarus, 1.0 μg / ml) effectively suppressed the cell vitality in 
cultures of anaplastic astrocytoma (51.4 ± 5.9%) and immature teratoma (90.6 ± 5.0%). Other 
substances – Methotrexate (Ebewe Artsnaym., Austria, 50.0 μg / ml) and Gemcitabine (Wee-
Em-Gee Pharmaceuticals Pvt. Ltd., India, 2.0 μg / ml) though were not included in the list of 
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leading substances, often successfully shared with them the second or third 
position. However, in a case of anaplastic oligodendroglioma the latter was not 
effective. Moreover, in its presence the cells of pleomorphic xanthoastrocytoma like 
Etoposide ones demonstrated a paradoxical reaction – a statistically significant increase of 
survival potential. The same is with carboplatin. Maximum susceptibility to it is shown by 
document in the samples of four neoplasm, and first of all of atypical teratoid / rabdoid 
tumor and optic chiasm glioma to have lost 79.5 ± 1.0 and 78.9 ± 4.1% viable units. These 
compounds are followed by Etoposide, which predominant efficacy was also recorded in 
three types of tumor cells, especially in glioblastoma.  
 
 
Fig. 4. Glioblastoma with marked vascular proliferation and the formation 
of glomerular structures. 
It is right to note the following fact: culture objects manifested almost the same (competitive) 
sensitivity to two or more agents in virtually all cases, if one takes into consideration the 
closeness of a number of infected cells, differences of which were not included in the 
validation category. As for β-NGF, its superiority (although not statistically significant) over 
the cytostatic regarding a number of perished in vitro units occurred in biopsies of 
pilomixoid astrocytoma (47.6 ± 1.3% vs. 40.9 ± 11.4% of Cisplatin), medulloblastoma (Fig. 5) 
(44.9 ± 2.9 vs. 41.6 ± 8.5% from the same preparation), oligoastrocytoma (78.3 ± 0.9 vs. 55.1 ± 
8.5% of Etoposide) (Fig. 3 a, b, c) and ependymoma (62.4 ± 6.0 vs. 58.6 ± 4.4% of 
Carboplatin). 
The efficiency of β-NGF (68.2 ± 0.5%) almost coincided with that of Cytarabine (68.9 ± 
11.9%), and under the contact with the cells of anaplastic astrocytomas (Fig. 6) (38.2 ± 2.3%) 
reached the 2nd position after for Cytarabine (54.4 ± 5.9%), pushing on the third place 
Carboplatin (35.9 ± 1.8%) when glioblastoma was applied to the cells the primary culture. In 
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the contrast, the derivatives of pleomorphic xanthoastrocytoma responded to β-NGF by a 
significant increase in its resistance to the toxin (an increase of vitality). Their death was 13.6 
± 2.9% in relation to the fixed one in the tumor cells which were not subjected to any 
influence – 31.7 ± 0.5%, whereas the culture of ganglioglioma was generally indifferent to 
cytostatics. 
 
 
Fig. 5. Undifferentiated medulloblastoma 
 
 
Fig. 6. Anaplastic astrocytoma. Moderate cellularity. Nuclear polymorphism 
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The access to the analysis of a destructive influence of combined test compounds 
application, while keeping in mind the possibility of potentiation of their individual effects 
was the logical corollary from an analysis of the brought materials. It turned out that in most 
combinations (excluding β-NGF + Methotrexate in the case of pilocytic astrocytoma), a 
marked tendency of a destructive cellular reactions increase in comparison with those 
described in the isolated introduction of preparation) was observed. A combination of 
Cisplatin + Etoposide (89.5 ± 0.8%), Carboplatin + Cytarabine (81.4 ± 2.0%), Carboplatin + 
Etoposide (69.2 ± 3.0%) and Cisplatin + Carboplatin (68.8 ± 7.3%) for cells oligoastrocytoma, 
and Cisplatin + Carboplatin (78.1 ± 1.9%) and β-NGF + Cisplatin (55.5 ± 3.2%) shown with 
an example of cells of ganglioglioma was especially attractive in vitro conditions. In these 
cases, the combined effect of cytotoxic drugs significantly exceeded observed ones under 
individual applications of each component from every pair of drugs. It’s worth noting that 
β-NGF, despite the decline of its performance in a variant of samples from 
oligoastrocytoma, tends as a rule to significantly increasing toxic effects on the tumor cells 
survival in a combination with cytotoxic drugs. This raises a question of reasonableness of 
the further research in terms of the simultaneous application of these agents. For the sake of 
fairness it should be emphasized that in any case of their combination one failed to reveal 
signs of synergy, where the reaction to the combination would have excelled the arithmetic 
sum of the personal effects, included as components in its structure. This can be conditioned 
by complex polymorphism of brain tumors, including dividing tumor cells and stem tumor 
cells at that. The survival of an even single cancer stem cell could lead to a recurrence of 
tumor metastasis and uncontrolled process in other parts of the central nervous system. 
It is important to point out that varying selective affinity touched not only biopsy samples 
belonging to different types of tumors, but also tumors taken away from an absolutely 
analogous composition accordingly to histological compounds and a measure of tumor 
progression. For example, the maximum destruction of cultured cells was recorded against a 
background application Cytarabine (68.3 ± 6.9%, P <0.05), and to a lesser extent Cisplatin 
(49.4 ± 5.4%, P <0.05), and Methotrexate (39.7 ± 7.2%, P <0.05) in three patients with 
medulloblastoma of the IV stage. The other chemotherapy drugs effect on cells of tumor had 
actually no difference in growth of cell culture without the application of cytostatic. This 
circumstance makes relevant carrying out a preliminary rapid assessment of individual 
susceptibility of patients to chemotherapeutic drugs with involvement of cultural systems. 
Moreover, it was possible to show by a document a certain correlation between the 
effectiveness of test compounds and the degree of malignancy at the same astrocytic nature 
of the tumors. Let us demonstrate this by the following examples. Thus Cisplatin (61.9 ± 
12.9%), Carboplatin (53.8 ± 7.9%) and Methotrexate (47.0 ± 7.2%) came into the triad of 
superior according to induction of cell lethality at the Ist stage. At the IInd stage Carboplatin 
(57.9 ± 5.9%), Methotrexate (51.1 ± 4.0%) and Cytarabine (50.2 ± 9.4%) occupied the 
dominant position. On the IIId – Cytarabine (54.4 ± 5.9%), Carboplatin (35.9 ± 1.8%) and 
Etoposide (34.5 ± 4.4%), and at the IVth – Cytarabine (68.9 ± 11.9%), Etoposide (63.1 ± 0.4%) 
and Gemcitabine (61.5 ± 1.7%). As a matter of fact the mentioned graduation should be 
viewed with a certain degree of conditionality, since statistically significant differences 
between the members of each triad could not be established. It’s noteworthy, however, that 
β-NGF, occupying a relatively modest position in the first phase of malignancy acquired a 
tough competition (68.2 ± 0.5%) leading to the IVth stage of Cytarabine (68.9 ± 11.9%) and 
bunched over (38.2 ± 2.3%) from the 2nd stage (35.9 ± 1.8%) of Carboplatin (please, bear in 
mind: at isolated applications of β-NGF).  
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The dependence of the destructive action of cytostatic and β-NGF also correlated with the 
age of the patients. Differences in digital indicators which characterize the percentage of cell 
loss of primary tumor culture in vitro gave evidence of the complex mechanisms of 
interaction between tumor cells with cytotoxic drugs coming in the triad of the most active 
compounds. So, at the child age under 3 years old the tumor generating effect was observed 
in Carboplatin (59.7 ± 4.1%), Cisplatin (51.4 ± 4.5%) and Cytarabine (48.3 ± 2.4%), and at the 
age from 4 to 6 years old β-NGF (63.2 ± 4.8%), Cisplatin (62.3 ± 7.6%) and Methotrexate (49.4 
± 5.8%) were in the lead. At the age from 7 to 10 years old the toxic substances rating looked 
like follows: Carboplatin (38.1 ± 8.8), β-NGF (27.1 ± 6.1%) and Methotrexate (26.2 ± 3.1%). At 
the age from 11 to 15 years old Methotrexate moved to the first position (56.0 ± 3.8%), 
slightly ahead of Carboplatin (54.4 ± 2.9%) and Cisplatin (53.6 ± 3.7%). β-NGF, taking the 
first place in terms of suppression of cell survival in the intermediate age groups, showed in 
the fourth (most mature) group an inverted effect, which increased cell survival significantly 
(13.3 ± 2.9%) compared with control (32.9 ± 3.0%). 
Experiments conducted in vitro demonstrated once again the well-known position of the 
highest individual sensitivity of glioma to cytostatics. No one has ever managed to fix the 
same sequence in the effectiveness of tumor destroying the action by the protocol approved 
cytostatic at absolutely identical histological diagnoses. Registered dependence of 
differences of effects from sex and age did not permit to explain the inner workings of such 
a high individual sensitivity of glioma to chemotherapy. It is obvious that one of 
explanations for this phenomenon can be a different degree of presence of stem tumor cells 
in tumor tissue. The high stability of stem tumor cells to damaging agents is well known. 
We are therefore got interested in the effect of enhancing the anticancer effect of cytostatics 
and NGF presence. As a hypothesis we can suggest that a strengthening of an anticancer 
effect of a combination of chemotherapeutic drugs and NGF is determined by an influence 
of drugs not only on dividing tumor cells but also on stem tumor cells. If it is so, then it is 
advisable to try to test different combinations of chemotherapy with cytotoxic substances of 
a new generation. In particular, we talk about the heterocyclic compounds, many of which 
are capable of inhibiting the intracellular tyrosine kinas path and, thus, to initiate the 
mechanisms of apoptosis in tumor tissue. The use of nanoparticles, in particular, Fullerenes 
or Dendrimers seems making a promise for these tasks. More details will be discussed 
below. There are many more challenges in oncology on the way to more effective cancer 
therapy. The well known high toxicity of chemotherapeutic drugs for all organs and systems 
of a living organism stimulates scientists and oncologists to find ways of reducing the 
general toxic action of cytostatic, and maintaining their anti-tumor effect. The result in these 
experiments on primary culture oligoastrocytoma cerebellar vermis can be given as an 
example of such a design. The data are presented in Table 1. 
The following fact draws attention at analyzing the data. In comparison with the natural 
death of cells the addition of Carboplatin, Methotrexate or Cisplatin was accompanied by an 
increase in the percentage of dead cells in a Petri dish from 35% to 47 % in the control (when 
cells of primary culture of oligoastrocytoma cerebellar vermis were developing in the 
culture medium without any contact with the chemotherapy). The combination of one of 
these three chemotherapy drugs with Nerve Growth Factor under decreasing doses of the 
cytostatic factor led in 10 times to the preservation or even an increase of the cytostatic effect 
(Table 1). The effect of two cytostatics - Carboplatin and Methotrexate increased especially 
www.intechopen.com
 Glioma – Exploring Its Biology and Practical Relevance 
 
476 
demonstratively. If you are not going to speculate on possible mechanisms of this 
phenomenon, then one is competent to conclude that the concentration of cytostatic can be 
significantly reduced in situations of combined use of chemotherapy with NGF. This 
reduction of dosage will be accompanied by a decline in general toxic action of 
chemotherapy drugs (which is critical for every cancer patient) and a persistence of the 
cytostatic action in relation to tumor cells (what is critical for a patient and a physician). A 
similar cytotoxic effect was observed earlier while applying diamond-like structures 
(Chekan et al., 2009). Experiments in vitro decreased survival of rat C6 glioma cells in the 
presence of implants made of titanium alloy VT-16. Putting diamond-like carbon coatings 
on the alloy VT-16 was accompanied with an increase in the percentage of cell death on the 
fifth day of cultivation, compared with the control: 39.9 ± 2.1% and 5.4 ± 0.3%, respectively. 
A more significant decrease in mitotic activity and cell viability was observed when C6 
glioma cells contacted with diamond-like carbon coating, comprising silver 
nanoparticles. The number of cell destruction of glioma C6 at contact with the diamond-like 
carbon covering, including up to 3.5 % Silver nanoparticles, made 53.7 ± 2.1%, and at doping 
up to 6.7 % Silver the cell destruction reached 66.7 ± 3.2% (P <0.05) in comparison with the 
control. Hence, the maximum toxic effect in regard to C6 glioma was detected in samples 
coated with diamond-like film, including silver nanoparticles. Similar results were obtained 
in the application of diamond coatings on the primary culture of human gliomas. If the 
surface of titanium samples with a diamond-like coatings included additional silver 
nanoparticles, the cytotoxic effect on the second day after exposure of cells of 
oligodendrogliomas with the surface of the samples would be disastrous for the viability of 
these cells. As it is shown in Fig. 7 A, processes of proliferation are continuing in tumor cells 
outside the titanium samples, while at the site location on a Petri dish of titanium sample 
almost all cells died (Fig. 7 B). 
 
 
Title Series Cell death, % 
Control 12.5 ± 4.2 
Carboplatin 4.0 μg / ml 35.3 ± 0.9* 
Carboplatin 0.4 μg / ml + β NGF 0.1 μg / ml 57.1 ± 12.5* 
Methotrexate 50.0 μg / ml 43.7 ± 8.6* 
Methotrexate 5.0 μg / ml + β NGF 0.1 μg / ml 72.4 ± 2.5* 
Cisplatin 1.0 μg / ml 47.4 ± 3.0* 
Cisplatin 0.1 μg / ml + β NGF 0.1 μg / ml 50.0 ± 8.1* 
 
Table 1. Percentage of cell death oligoastrocytoma cerebellar vermis at a combination of 
different doses of cytostatics with Nerve Growth Factor (NGF). (The asterisk * denotes the 
reliability of P <0.05) 
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Fig. 7. Oligodendrogliomas cell distribution in twenty-four hours at 40 mm from the 
titanium sample with diamond-like coating containing silver nanoparticles (A), and at 1 mm 
from the edge of the sample (B) 
It was established that if the titanium samples were coated with titanium dioxide (TiO2), a 
cytotoxic effect of these samples (Fig. 8 A and B) would not differ from a cytotoxic effect of 
those which coating consisted of silver nanoparticles. 
 
Fig. 8. Oligodendrogliomas cell distribution in twenty-four hours at 40 mm from the 
titanium sample with titanium dioxide (TiO2) (A), and at 1 mm from the edge of the sample 
(B) 
A B
A B
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The highest potentiating effect of the combination of chemotherapy and nanoparticles was 
obtained by the application of Dendrimers. Series of experiments of a Cisplatin combination 
with PAMAM on the primary culture of medulloblastoma are in Table 2. 
 
Title Series Cell death, % 
Control 20.7 ± 3.3 
Cisplatin 1.0 μg / ml 67.6 ± 7.4* 
Cisplatin 1.0 μg / ml + β NGF 0.1 μg / ml 49.2 ± 6.8* 
PAMAM 30 mM (10.0 μl ) 45.5 ± 6.7* 
Cisplatin 1.0 μg / ml + PAMAM 30 mM 
(10.0 μl ) 
92.7 ± 4.9* 
Cisplatin 0.1 μg / ml + PAMAM 30 mM 
(10.0 μl ) 
98.4 ± 1.5* 
Table 2. Percentage of cell death medulloblastoma IV at a combination of different doses of 
Cisplatin with Polyamidoamine (PAMAM) Dendrimer (the asterisk * denotes the reliability 
of P <0.05) 
As it is seen in Table 2, the percentage of cell death of malignant medulloblastoma increased 
significantly in primary culture under the action of Cisplatin and paradoxically reduced by 
a combination of Cisplatin with NGF. This fact does illustrate once again the high specificity 
of each particular tumor in each patient, what determines the choice of individual treatment 
strategy in each case. This choice should be guided by research data and the sensitivity of 
cells in primary culture in vitro.  
Application of PAMAM 30 mM (10.0 μl) in a Petri dish was accompanied by increased cell 
death in comparison with control ones. In principle, the anticancer effect of Dendrimer is 
described in literature but has not been studied in detail (Bei et al., 2010). At this stage we 
have only stated such an action of PAMAM. Surprisingly a stable toxic effect of a 
combination Cisplatin with PAMAM was demonstrated at using two different 
concentrations of chemotherapeutic drugs (Table 2). The anticancer effect of this drug 
combination ranged from 92% to 98% (Fig. 9, and Fig. 10). Therefore it is very 
important to find such a combination chemotherapy with growth factors and nanoparticles, 
which would reduce the dose of cytostatics, when we tried to determine the sensitivity of 
individual tumor in vitro to cytostatic in the next phase of the research. At the same 
cytotoxic effect of substances used must be maintained at maximum levels. Dendrimers 
belong to a class of polymeric compounds whose molecules have a large number of 
branches. At their acquisition a number of branches of the molecule increase with every 
elementary act of growth. As a result, the shape and rigidity of the molecules change with 
increasing molecular weight of these compounds, what is usually accompanied with 
changes in physical and chemical properties of Dendrimers. Inside Dendrimers cavities are 
formed which can be filled in with a variety of substances, such as cytostatic. This ability of 
Dendrimers was one of the factors to determine the decision to use them for enhancement of 
their anticancer effect of chemotherapy. 
The paper drew attention also to other compounds that might be effective against tumor 
growth. The input material for the synthesis of heterocyclic compounds was 1,2-azole-3-
carboxylic acids, which were consistently converted into azides or carbamide. Implemented 
computer modeling of ligand-protein complexes of carbamide was carried out in the 
framework of the methods of molecular mechanics using the program Dock 6.4 and USF 
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Chimera. Evaluation of energy characteristics of the van der Waals and electrostatic 
interaction suggests the possibility of efficient binding of 1,2-azole ligand protein. These 
studies helped to choose the best version of heterocyclic compounds (Carbamide), which 
application in a combination with cytostatic agents and Nerve Growth Factor allowed 
reducing the dose of the cytostatic factor in 10 times at maintaining in vitro the tumor 
generating effect on primary cell cultures. There are the above listed drawings as a 
demonstration. 
 
 
Fig. 9. Atypical teratoid / rhabdoid tumor cells remaining in a day after the application of 
Cisplatin (1.0 μg / ml), β-NGF (0.1 μg / ml), Polyamidoamine Dendrimer (30 mM, 10.0 μl) 
 
 
Fig. 10. Atypical teratoid / rhabdoid tumor cells remaining in a day after the application of 
Cisplatin (0.1 μg / ml), β-NGF (0.1 μg / ml), Polyamidoamine Dendrimer (30 mM, 10.0 μl) 
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Anticancer effects of heterocyclic compounds in one more series of experiments were 
approved (Figs. 11-13). The Fig. 11 shows the primary tumor cells of pilocytic astrocytoma in 
two days after passage. Figure 12 shows primary tumor cells pilocytic astrocytoma in two 
days after the addition of Azide at a concentration of 1.0 mg / ml. Figure 13 shows primary 
tumor cells pilocytic astrocytoma in two days after the addition of Carbamide at a 
concentration of 1.0 mg / ml. Toxic properties of Azides and Carbamide can be explained by 
their ability to inhibit the tyrosine kinase pathway. This mechanism can be implemented in 
the subsequent initiation of apoptosis in tumor cells. 
 
 
Fig. 11. Pilocytic astrocytoma cells in a day after passage 
 
 
Fig. 12. Pilocytic astrocytoma cells in a day after application of Azide at a concentration of 
1.0 mg / ml 
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Fig. 13. Pilocytic astrocytoma cells in a day after application of Carbamide at a concentration 
of 1.0 mg / ml 
4. Conclusion 
The data obtained are the basis to discuss several aspects of increasing the chemotherapy 
effectiveness problem. Being general toxic poisons in the action by their nature, 
chemotherapy drugs come out as an essential attribute of anticancer therapy in accordance 
with the majority of the approved treatment protocols. There are no alternatives to their use 
considering the presence of appropriate evidence. In such a case, how can one reduce the 
general antineoplastic action of cytostatics and keep their strong anticancer effect? The 
anticancer effect is under discussion in respect of not only dividing tumor cells, but also 
stem tumor cells. The advantage of a mutual use of cytostatics and NGF compared with 
their individual use was confirmed in the work. It puts on the agenda the top-priority 
intensively developing problem, that is of improving the permeability of the blood-brain 
barrier at systemic application of chemotherapy and the search for "circuitous" ways to the 
desired delivery of biologically active compounds to tumor tissues (Alam et al., 2010; Chen 
et al., 2011; Gerstner & Fine, 2007). In order to implement the first plan several directions are 
supposed. One of them is to attract hyperosmotic solutions containing histamine, 
bradykinin, mannitol and so on, which will contribute to achieving the cytostatic targets in 
the brain at their systematic putting into operation (Kemper et al., 2004; Xie et al., 2005). But 
the transient opening by them of the entrance gate provides at the same time an opportunity 
of entering via them for the neurotoxic substance what is especially dangerous in case of a 
more complex operative procedure of an intracarotid infusion of chemotherapeutic agents. 
This may be accompanied by disorders of speech, movement, visual perception. 
One more trend is based on creation of conjugates of an active commencement with 
proteins, which are able to recognize the integral components of cerebrovascular structures, 
such as antibodies to the receptor ferritin in relation to the NGF. This ensures its 
effectiveness in a rank of low concentrations. The simultaneous application of anticancer 
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drugs with inhibitors of a large glycoprotein P, which prevents the movement of cytotoxic 
drugs through the blood-brain barrier (Gerstner & Fine, 2007; Kemper et al., 2004) is 
promising. Preclinical trials with Paclitaxel have confirmed the perspectives of such a 
method, making reasonable transition to clinical trials.  
Attempts of a different kind are being made, namely the involvement of the bradykinin 
analog BMP-7, endowed with a more extended half-life period and with selectivity in 
respect to the receptor B2 in comparison with the being endogenously synthesized 
compound (Kemper et al., 2004; Ta et al., 2009; Xie et al., 2005). Being associated with them, 
BMP-7 leads to the opening of calcium channels in cells, an increase in their level of free 
cations. That leads to a reaction of endothelial cells and to weakening of intercellular 
contacts. The vascular permeability increases in addition. The recorded concentrations of 
growth factors were achieved in 30 minutes with the highest representation in the striatum, 
hippocampus, cerebral cortex and relatively low concentrations in the olfactory bulb, 
cerebellum and brainstem at joint custody of NGF and BMP-7 into stabilized liposomes, 
which are smaller than 100 nm. There was a good agreement between the permeability 
coefficient of the drug and its targeted action (Xie et al., 2005) at that. Under intracarotid 
administration of BMP-7 with Carboplatin in rat models of gliomas such a combination has 
significantly reduced the number of cytostatic normally used in humans. Phase II in clinical 
trials conducted on 87 patients with recurrence of malignant gliomas recorded a noticeable 
advantage of processing BMP-7 + Carboplatin before individually using only Carboplatin. 
The advances in molecular biology and genetic engineering, which ensured the 
implementation of experimental and clinical use of low molecular weight peptides, proteins, 
oligonucleotides, monoclonal antibodies, etc. (Kruttgen et al., 2006; Xie et al., 2005) 
contributed to considerable progress in the development of a "roundabout" ways of delivery 
of drugs. In total they have created a fertile ground not only for in-depth understanding the 
basic mechanisms of carcinogenesis, but also simultaneously for widening the means of 
early diagnosis, the front of anticancer attack and optimization of medical schemes. 
In a series of widely exploited methods there is a stereotactic implantation in the bed, 
formed after excision of tumor, indifferent biodegradable polymer substrates, impregnated 
in that or another way with an active principle. In this case, the cytostatic penetrates in 
measured doses into the surrounding tissue during a long period of time and destroy the 
remaining infected cells (Kemper et al., 2004; Ta et al., 2009). The concentration of drugs, 
developed in this case, can exceed observed ones with intravenous injection from 4 to 1200 
times. In one of the clinical trial performed on 222 adult patients with recurrent gliomas 
mortality of persons who were within 6 months receiving such a method Cisplatin was 44% 
versus 67% among patients treated with placebo (P < 0.02). 
The use of polymer capsules can also supply the brain with cells (transfected with viral 
vectors) which express a particular desired target gene which products act targeteous on the 
relevant parts of oncogenesis. The primary fibroblasts, astrocytes, ependimocytes, stem or 
progenitor cells serve as usual objects. For example, subclones Cyclin-Dependent Kinase 2 
Interacting Protein (CINP) releasing in vitro NGF at 2 ng/ h/10-5 cells over 10 weeks was 
isolated from conventionally immortalized progenitor neuroblasts of the central nervous 
system of rat embryos with embedded DNA of growth factors. Being introduced into the 
brain such cells survived well, migrated at a distance of 15 mm from the implant site and 
integrated with the host tissue without any signs of growth or tumor formation. 
Thus, we can conclude: 
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i. Sensitivity of glioma cells to chemotherapeutic agents, Nerve Growth Factor, and 
Dendrimers, Diamond like coated samples, heterocyclic compaunds in vitro depends on 
the origin, histological type tumors, the degree of malignancy, age and individual 
characteristics of patients; 
ii. Combined application of Nerve Growth Factor and chemotherapy increases the 
percentage of dying in a culture of cellular elements; 
iii. A complementary effect of Nerve Growth Factor appears to enhance cytotoxic effects of 
chemotherapy. This addictiveness reduces the effective dose of cytotoxic drugs in more 
than 10 times; 
iv. The presence of growth factor and/or Dendrimers, heterocyclic compounds do reduce 
the toxic dose of the chemotherapeutic drugs simultaneously maintaining a high 
cytostatic effect; 
v. Detection in vitro of high individual sensitivity of brain tumors to cytostatics confirms 
the hypothesis concerning polymorphism in mechanisms of carcinogenesis; 
vi. It is appropriate to take into account the results of experiments in order to determine 
the sensitivity of tumor cells of primary culture to cytostatic drugs in the development 
of new specialized treatment protocols for brain tumors (mono- or polychemotherapy).  
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